Full-Time
Develops and commercializes prescription medicines
No salary listed
Senior, Expert
Orlando, FL, USA + 8 more
More locations: Knoxville, TN, USA | Tampa, FL, USA | Miami, FL, USA | Raleigh, NC, USA | Richmond, VA, USA | Columbia, SC, USA | Atlanta, GA, USA | Roanoke, VA, USA
Upload your resume to see how it matches 10 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
AstraZeneca focuses on discovering, developing, and selling prescription medicines, primarily in three areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Their products are developed through extensive research and development, which includes rigorous clinical trials and regulatory approvals before reaching the market. AstraZeneca differentiates itself from competitors by investing heavily in scientific research and fostering collaborations through initiatives like their Open Innovation program, which shares resources with the scientific community to speed up drug discovery. The company's goal is to advance healthcare by creating effective treatments for serious diseases and expanding their product offerings through strategic partnerships.
Company Size
10,001+
Company Stage
IPO
Headquarters
Cambridge, United Kingdom
Founded
1913
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Flexible Work Hours
Calquence recommended for EU approval in 1L MCL
Recommendation based on ECHO Phase III trial results which demonstrated over 16 months of progression-free survival improvement vs. chemoimmunotherapy alone. AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous hematopoietic stem cell transplantation. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on the results from the ECHO Phase III trial which were presented at the European Hematology Association 2024 Congress
Imfinzi approved in the US for bladder cancer
Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant chemotherapy alone. AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in the US for the treatment of adult patients with muscle-invasive bladder cancer (MIBC). The approval was granted by the Food and Drug Administration (FDA) after securing Priority Review and was based on results from the NIAGARA Phase III trial which were presented during a Presidential Symposium at the 2024 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine
Sunil Verma, Global Head of Oncology, Medical at AstraZeneca's Oncology Business Unit, shared on LinkedIn: